Literature DB >> 23925680

Naltrexone may block euphoria-like placebo effect.

Andriy V Samokhvalov1, Islam Gamaleddin, Beth Sproule, Jürgen Rehm.   

Abstract

Naltrexone is a first-line treatment for alcohol use disorders in North America and Europe. It was prescribed to a 63-year-old patient in order to help control amounts of alcohol consumed per drinking occasion. The patient experienced a paradoxical, but consistent side effect of feeling inebriated each time he took naltrexone. In order to investigate this phenomenon we administered naltrexone and a placebo in a randomised double-blind fashion. The patient exhibited a 'high-like' response to all placebo capsules and a decrease in the subjectively perceived euphoria shortly after ingestion of naltrexone. Given that this placebo effect could be mediated via opioid receptors we suggest that this case illustrates the ability of naltrexone to eliminate the placebo effect. This feature of naltrexone, upon further investigation, might be used in randomised clinical trials in addition to or as an alternative to a placebo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23925680      PMCID: PMC3762058          DOI: 10.1136/bcr-2013-010098

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  Neurobiological mechanisms of the placebo effect.

Authors:  Fabrizio Benedetti; Helen S Mayberg; Tor D Wager; Christian S Stohler; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2005-11-09       Impact factor: 6.167

2.  Introduction to placebo effects in medicine: mechanisms and clinical implications.

Authors:  Karin Meissner; Niko Kohls; Luana Colloca
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-06-27       Impact factor: 6.237

3.  A simultaneous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls.

Authors:  M A Schuckit; E O Gold
Journal:  Arch Gen Psychiatry       Date:  1988-03

4.  Placebo effects mediated by endogenous opioid activity on mu-opioid receptors.

Authors:  Jon-Kar Zubieta; Joshua A Bueller; Lisa R Jackson; David J Scott; Yanjun Xu; Robert A Koeppe; Thomas E Nichols; Christian S Stohler
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

5.  Activation of the opioidergic descending pain control system underlies placebo analgesia.

Authors:  Falk Eippert; Ulrike Bingel; Eszter D Schoell; Juliana Yacubian; Regine Klinger; Jürgen Lorenz; Christian Büchel
Journal:  Neuron       Date:  2009-08-27       Impact factor: 17.173

Review 6.  Naltrexone for the management of alcohol dependence.

Authors:  Raymond F Anton
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

Review 7.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.